Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Coronavirus Disease 2019 (COVID-19) is a newly emerged disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic is having a large impact on the mental and physical health of patients, yet data on the quality of life of post-COVID-19 patients is lacking. There are currently no post-COVID-19 specific measures for quality of life, particularly none which include the views of post-COVID-19 patients themselves. This observational study will recruit participants to contribute their preferences to the creation of a post-COVID-19 specific patient-reported measure on post-COVID-19 quality of life. Participants will be split into three groups: those who were not hospitalised; those who were hospitalised but not in intensive care units; and those who were hospitalised and in intensive care units. The creation of this measure will form phase 1 of the study, with 30-60 participants (10-20 in each group above) recruited to complete online surveys to find out their preferences of areas of life to include in such a measure. This will involve 3 online surveys, 1) to ask which areas of life they feel are impacted and how; 2) to find consensus about the areas to be included; 3) to weight the relevance of these areas in relation to each other. In phase 2 recruitment will open to additional participants and all participants will be asked to complete the finalised post-COVID-19 quality of life measure once a month for 12 months, aiming for a minimum of 100 participants at this stage. All participants will also be asked to complete a demographic questionnaire to inform the analysis of the data.

Who May Be Eligible (Plain English)

Phase One Who May Qualify: - The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection - The participant is aged 18 years or older - The participant is capable of providing willing to sign a consent form - The participant can read, write and converse in English - The participant can comply with the study schedule Who Should NOT Join This Trial: - The participant does not have a confirmed COVID-19 test or antibody test - The participant is aged under 18 years - The participant is not capable of giving willing to sign a consent form - The participant is unable to read, write and converse in English - The participant is unable to comply with study schedule data collection Phase Two Who May Qualify: - The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection or a clinical diagnosis of COVID-19 - The participant is aged 18 years or older - The participant is capable of providing willing to sign a consent form - The participant can read, write and converse in English - The participant can comply with the study schedule Who Should NOT Join This Trial: - The participant does not have a confirmed COVID-19 test or antibody test or clinical diagnosis of COVID-19 - The participant is aged under 18 years - The participant is not capable of giving willing to sign a consent form - The participant is unable to read, write and converse in English - The participant is unable to comply with study schedule data collection Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Phase One Inclusion Criteria: * The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection * The participant is aged 18 years or older * The participant is capable of providing informed consent * The participant can read, write and converse in English * The participant can comply with the study schedule Exclusion Criteria: * The participant does not have a confirmed COVID-19 test or antibody test * The participant is aged under 18 years * The participant is not capable of giving informed consent * The participant is unable to read, write and converse in English * The participant is unable to comply with study schedule data collection Phase Two Inclusion Criteria: * The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection or a clinical diagnosis of COVID-19 * The participant is aged 18 years or older * The participant is capable of providing informed consent * The participant can read, write and converse in English * The participant can comply with the study schedule Exclusion Criteria: * The participant does not have a confirmed COVID-19 test or antibody test or clinical diagnosis of COVID-19 * The participant is aged under 18 years * The participant is not capable of giving informed consent * The participant is unable to read, write and converse in English * The participant is unable to comply with study schedule data collection

Treatments Being Tested

OTHER

No intervention - quality of life measure

Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months

Locations (1)

Medialis
Oxford, United Kingdom